ABIVAX Société Anonyme Future Growth

Future criteria checks 2/6

ABIVAX Société Anonyme's earnings are forecast to decline at 19.1% per annum while its annual revenue is expected to grow at 54.3% per year. EPS is expected to decline by 0.02% per annum.

Key information

-19.1%

Earnings growth rate

-0.02%

EPS growth rate

Biotechs earnings growth	27.8%
Revenue growth rate	54.3%
Future return on equity	n/a
Analyst coverage	Low
Last updated	29 Nov 2023

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:ABVXp - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	2	-149	-144	-172	4
12/31/2024	2	-124	-126	-134	4
12/31/2023	2	-107	-109	-110	4
6/30/2023	0	-92	-57	-57	N/A
3/31/2023	0	-76	-56	-55	N/A
12/31/2022	N/A	-61	-54	-54	N/A
9/30/2022	2	-50	N/A	N/A	N/A
6/30/2022	2	-47	-46	-46	N/A
3/31/2022	1	-45	-46	-46	N/A
12/31/2021	N/A	-42	-45	-45	N/A
9/30/2021	0	-41	N/A	N/A	N/A
6/30/2021	0	-39	-46	-45	N/A
3/31/2021	0	-38	-38	-38	N/A
12/31/2020	0	-38	-31	-30	N/A
9/30/2020	0	-35	N/A	N/A	N/A
6/30/2020	0	-32	-25	-24	N/A
3/31/2020	0	-31	-27	-26	N/A
12/31/2019	0	-31	-28	-27	N/A
9/30/2019	0	-27	-23	-22	N/A
6/30/2019	0	-23	-18	-17	N/A
3/31/2019	1	-19	-17	-16	N/A
12/31/2018	1	-16	-15	-15	N/A
9/30/2018	1	-14	-14	-13	N/A
6/30/2018	1	-13	-12	-11	N/A
3/31/2018	1	-12	-11	-10	N/A
12/31/2017	0	-11	-9	-8	N/A
9/30/2017	0	-11	N/A	N/A	N/A
6/30/2017	0	-12	-12	-11	N/A
3/31/2017	0	-13	N/A	-14	N/A
12/31/2016	0	-14	N/A	-16	N/A
9/30/2016	0	-16	N/A	N/A	N/A
6/30/2016	0	-17	N/A	-24	N/A
3/31/2016	0	-17	N/A	-19	N/A
12/31/2015	0	-16	N/A	-15	N/A
9/30/2015	0	-14	N/A	N/A	N/A
6/30/2015	0	-12	N/A	N/A	N/A
3/31/2015	0	-8	N/A	N/A	N/A
12/31/2014	0	-5	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ABVXp is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ABVXp is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ABVXp is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ABVXp's revenue (54.3% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: ABVXp's revenue (54.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ABVXp's Return on Equity is forecast to be high in 3 years time

ABIVAX Société Anonyme Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Forecast breakeven date moved forward to 2022

Forecast to breakeven in 2024

Recent updates

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Insufficient new directors

Insufficient new directors

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Insufficient new directors

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Insufficient new directors

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €28.90

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies